review article | Q7318358 |
scholarly article | Q13442814 |
P356 | DOI | 10.1038/NRGASTRO.2016.144 |
P698 | PubMed publication ID | 27826137 |
P50 | author | Julien Dimastromatteo | Q57010216 |
P2093 | author name string | Kimberly A Kelly | |
Teresa Brentnall | |||
P2860 | cites work | Targeted nanoparticles for imaging incipient pancreatic ductal adenocarcinoma | Q21144653 |
Toxicity of MRI and CT contrast agents | Q22306013 | ||
Plectin-1 as a novel biomarker for pancreatic cancer | Q24615622 | ||
Distant metastasis occurs late during the genetic evolution of pancreatic cancer | Q24624284 | ||
Prevalence of unsuspected pancreatic cysts on MDCT | Q24650018 | ||
The course of traumatic pancreatitis in a patient with pancreas divisum: a case report | Q24792750 | ||
Pathways for aberrant angiogenesis in pancreatic cancer | Q24800215 | ||
The Rationale for Insulin Therapy in Alzheimer's Disease | Q26744834 | ||
Endoscopic retrograde pancreatography: When should we do it? | Q26795778 | ||
Imaging preoperatively for pancreatic adenocarcinoma | Q26799450 | ||
Cancer statistics, 2010 | Q27860525 | ||
Challenges of Pancreatic Cancer | Q28080671 | ||
Carbohydrate-mediated cell adhesion in cancer metastasis and angiogenesis | Q28260742 | ||
Genetic risk factors for type 1 diabetes | Q28276356 | ||
Efficacy of gemcitabine plus axitinib compared with gemcitabine alone in patients with advanced pancreatic cancer: an open-label randomised phase II study | Q28282189 | ||
Expression and distribution of insulin-like growth factor-1 receptor in human carcinomas | Q79079222 | ||
A selective approach to resection of cystic lesions of the pancreas: results from 539 consecutive patients | Q80212089 | ||
Endoscopic retrograde cholangiopancreatography, intraductal ultrasonography, and magnetic resonance cholangiopancreatography in bile duct strictures: a prospective comparison of imaging diagnostics with histopathological correlation | Q80495368 | ||
Cystic neoplasms of the pancreas | Q80571894 | ||
¹⁸F-FDG PET/CT imaging of the pancreas: spectrum of diseases | Q82450093 | ||
Ex vivo imaging of pancreatic beta cells using a radiolabeled GLP-1 receptor agonist | Q83587301 | ||
Contrast-enhanced ultrasound in the staging of acute pancreatitis | Q84373467 | ||
Quantitative endoscopic ultrasound elastography: an accurate method for the differentiation of solid pancreatic masses | Q84519589 | ||
Quantitative elastography associated with endoscopic ultrasound for the diagnosis of chronic pancreatitis | Q85708512 | ||
Pancreatic Intraepithelial Neoplasia | Q38720267 | ||
Projecting cancer incidence and deaths to 2030: the unexpected burden of thyroid, liver, and pancreas cancers in the United States | Q39190004 | ||
The effect of PPAR-gamma agonist on (18)F-FDG uptake in tumor and macrophages and tumor cells | Q39855354 | ||
Monitoring response to anticancer therapy by targeting microbubbles to tumor vasculature | Q40187867 | ||
[Lys40(Ahx-DTPA-111In)NH2]exendin-4, a very promising ligand for glucagon-like peptide-1 (GLP-1) receptor targeting. | Q40202365 | ||
Regulation of vascular endothelial growth factor receptor-2 expression in pancreatic cancer cells by Sp proteins | Q40283138 | ||
Synergistic antitumor effects of combined epidermal growth factor receptor and vascular endothelial growth factor receptor-2 targeted therapy | Q40293653 | ||
Endoscopic ultrasonography in the diagnosis of chronic pancreatitis | Q41117246 | ||
A conservative and minimally invasive approach to necrotizing pancreatitis improves outcome | Q41981442 | ||
Exocrine pancreatic function assessed by secretin cholangio-Wirsung magnetic resonance imaging | Q43432850 | ||
An assessment of the severity of interstitial pancreatitis | Q44018891 | ||
Pancreatic multicenter ultrasound study (PAMUS). | Q44449682 | ||
Off-label use of ultrasound contrast agents for abdominal imaging in the United States. | Q45828191 | ||
In vivo imaging of transplanted islets with 64Cu-DO3A-VS-Cys40-Exendin-4 by targeting GLP-1 receptor | Q46273024 | ||
Pancreatic beta-cell mass in European subjects with type 2 diabetes | Q46332814 | ||
In vivo and in vitro glucose-induced biphasic insulin secretion in the mouse: pattern and role of cytoplasmic Ca2+ and amplification signals in beta-cells | Q46917075 | ||
Incidence and diagnostic significance of minor pathologic changes in the adult pancreas at autopsy: a systematic study of 112 autopsies in patients without known pancreatic disease | Q47605910 | ||
The incidence and clinical relevance of chronic inflammation in the pancreas in autopsy material | Q50148878 | ||
Combination of EUS-FNA and elastography (strain ratio) to exclude malignant solid pancreatic lesions: A prospective single-blinded study. | Q50438883 | ||
Synthesis and evaluation of optical and PET GLP-1 peptide analogues for GLP-1R imaging. | Q51744152 | ||
Periductal stromal collagen topology of pancreatic ductal adenocarcinoma differs from that of normal and chronic pancreatitis. | Q51784964 | ||
Interstitial fibrosis in the pancreas. | Q52533934 | ||
Quantification of pancreatic exocrine function with secretin-enhanced magnetic resonance cholangiopancreatography: normal values and short-term effects of pancreatic duct drainage procedures in chronic pancreatitis. Initial results. | Q52979319 | ||
Imaging of Acute Pancreatitis. | Q52989354 | ||
Quantitative analysis of tissue perfusion using contrast-enhanced transabdominal ultrasound (CEUS) in the evaluation of the severity of acute pancreatitis. | Q53252050 | ||
Contrast enhanced transabdominal ultrasound in the characterisation of pancreatic lesions with cystic appearance. | Q53274128 | ||
[Lys40(Ahx-DTPA-111In)NH2]-Exendin-4 is a highly efficient radiotherapeutic for glucagon-like peptide-1 receptor-targeted therapy for insulinoma. | Q53332122 | ||
Detection of small pancreatic tumors with multiphasic helical CT. | Q53631026 | ||
Endosonography-guided fine needle aspiration biopsy in the evaluation of pancreatic masses. | Q53676849 | ||
Acute pancreatitis | Q56094875 | ||
Comparison of Contrast-Enhanced Sonography and MRI in Displaying Anatomic Features of Cystic Pancreatic Masses | Q57820258 | ||
A Selective Approach to Resection of Cystic Lesions of the Pancreas: Results From 539 Consecutive Patients | Q57846082 | ||
Inflammatory pancreatic masses. Problems in differentiating focal pancreatitis from carcinoma | Q71249655 | ||
Serum lipase levels in nonpancreatic abdominal pain versus acute pancreatitis | Q71600636 | ||
Acute renal failure as a complication of acute pancreatitis | Q71695409 | ||
Chronic pancreatitis | Q72214015 | ||
Acceleration of autoimmune diabetes by cyclophosphamide is associated with an enhanced IFN-gamma secretion pathway | Q73239275 | ||
Constitutive Sp1 activity is essential for differential constitutive expression of vascular endothelial growth factor in human pancreatic adenocarcinoma | Q73894010 | ||
Staging and treatment for patients with pancreatic cancer. How small is an early pancreatic cancer? | Q77323900 | ||
Enhanced expression of vascular endothelial growth factor in human pancreatic cancer correlates with local disease progression | Q77554681 | ||
Dual-phase helical CT of pancreatic adenocarcinoma: assessment of resectability before surgery | Q77800395 | ||
Microenvironmental regulation of tumor progression and metastasis | Q29615504 | ||
Role of the vascular endothelial growth factor pathway in tumor growth and angiogenesis | Q29620559 | ||
Early detection of sporadic pancreatic cancer: summative review | Q30300012 | ||
Unexpected gain of function for the scaffolding protein plectin due to mislocalization in pancreatic cancer | Q30412956 | ||
Manganese-enhanced magnetic resonance imaging detects declining pancreatic β-cell mass in a cyclophosphamide-accelerated mouse model of type 1 diabetes | Q30415463 | ||
Vascular endothelial growth factor receptor type 2-targeted contrast-enhanced US of pancreatic cancer neovasculature in a genetically engineered mouse model: potential for earlier detection | Q30416185 | ||
Epidemiology of chronic pancreatitis: burden of the disease and consequences | Q30427447 | ||
Development of Secreted Protein and Acidic and Rich in Cysteine (SPARC) Targeted Nanoparticles for the Prognostic Molecular Imaging of Metastatic Prostate Cancer | Q30428429 | ||
Microbubbles in medical imaging: current applications and future directions | Q30433669 | ||
Noninvasive assessment of pancreatic beta-cell function in vivo with manganese-enhanced magnetic resonance imaging | Q30436863 | ||
Contrast-enhanced ultrasonograpic findings in pancreatic tumors | Q30493904 | ||
Tumor imaging by means of proteolytic activation of cell-penetrating peptides | Q33569121 | ||
Surgery with molecular fluorescence imaging using activatable cell-penetrating peptides decreases residual cancer and improves survival | Q33732828 | ||
Pancreatic cystic lesions: The value of contrast-enhanced endoscopic ultrasound to influence the clinical pathway | Q33780486 | ||
Imaging diagnosis of pancreatic cancer: a state-of-the-art review | Q33801389 | ||
Results of a phase I-II study on intraductal confocal microscopy (IDCM) in patients with common bile duct (CBD) stenosis | Q33851876 | ||
Targeted delivery of gas-filled microspheres, contrast agents for ultrasound imaging | Q33904256 | ||
Alzheimer's disease is type 3 diabetes-evidence reviewed | Q34020000 | ||
Targeting of ultrasound contrast material. An in vitro feasibility study | Q34064964 | ||
Radiologic and near-infrared/optical spectroscopic imaging: where is the synergy? | Q34357133 | ||
American College of Gastroenterology guideline: management of acute pancreatitis | Q34360523 | ||
In vivo imaging of GLP-1R with a targeted bimodal PET/fluorescence imaging agent | Q34434122 | ||
Clinical practice. Acute pancreatitis | Q34527560 | ||
Tumor angiogenic marker expression levels during tumor growth: longitudinal assessment with molecularly targeted microbubbles and US imaging | Q34591102 | ||
EUS-based criteria for the diagnosis of chronic pancreatitis: the Rosemont classification | Q34604850 | ||
Pancreatic cancer in chronic pancreatitis; aetiology, incidence, and early detection | Q34620078 | ||
Pancreatitis as a risk for pancreatic cancer | Q34756078 | ||
Applying PET to broaden the diagnostic utility of the clinically validated CA19.9 serum biomarker for oncology | Q34762185 | ||
Molecular imaging in drug discovery and development | Q35058563 | ||
Accurate measurement of pancreatic islet beta-cell mass using a second-generation fluorescent exendin-4 analog | Q35149660 | ||
Comparison of ERCP, EUS, and ERCP combined with EUS in diagnosing pancreatic neoplasms: a systematic review and meta-analysis | Q35180411 | ||
The glucagon-like peptides: a double-edged therapeutic sword? | Q35181801 | ||
Epidemiology, diagnosis, and management of cystic lesions of the pancreas | Q35325612 | ||
Ratiometric activatable cell-penetrating peptides label pancreatic cancer, enabling fluorescence-guided surgery, which reduces metastases and recurrence in orthotopic mouse models | Q35335567 | ||
Noninvasive MRI of β-cell function using a Zn2+-responsive contrast agent. | Q35546868 | ||
Intraductal papillary mucinous tumors of the pancreas: biology, diagnosis, and treatment | Q35583848 | ||
Target therapy using a small molecule inhibitor against angiogenic receptors in pancreatic cancer | Q35668675 | ||
Utility of Contrast-Enhanced Transabdominal Ultrasonography to Diagnose Early Chronic Pancreatitis | Q35674396 | ||
Detection of circulating pancreas epithelial cells in patients with pancreatic cystic lesions | Q35887807 | ||
Confocal endomicroscopy: Is it time to move on? | Q35898662 | ||
Proteomic profiling of pancreatic cancer for biomarker discovery | Q36026306 | ||
Site-specifically labeled CA19.9-targeted immunoconjugates for the PET, NIRF, and multimodal PET/NIRF imaging of pancreatic cancer. | Q36435260 | ||
Ultrasonography of the pancreas. 4. Contrast-enhanced imaging | Q36534842 | ||
What Is the Best Way to Identify Malignant Transformation Within Pancreatic IPMN: A Systematic Review and Meta-Analyses | Q36751497 | ||
Glypican-1 identifies cancer exosomes and detects early pancreatic cancer | Q36781050 | ||
Is an Oral Glucose Tolerance Test Still Valid for Diagnosing Diabetes Mellitus? | Q36858458 | ||
Contrast-enhanced sonography in pancreatic diseases | Q36942399 | ||
Chronic pancreatitis: ultrasound, computed tomography, and magnetic resonance imaging features | Q36985797 | ||
IGF1 Receptor Targeted Theranostic Nanoparticles for Targeted and Image-Guided Therapy of Pancreatic Cancer | Q37007341 | ||
Radiology of pancreatic adenocarcinoma: current status of imaging | Q37048730 | ||
Pancreatic cancer--EUS and early diagnosis | Q37076131 | ||
Pancreatic cancer: from molecular signature to target therapy | Q37147525 | ||
Detection of pancreatic ductal adenocarcinoma in mice by ultrasound imaging of thymocyte differentiation antigen 1. | Q37198592 | ||
Preclinical evaluation of a novel CEA-targeting near-infrared fluorescent tracer delineating colorectal and pancreatic tumors. | Q37366754 | ||
Pancreatic neuroendocrine tumours: hypoenhancement on arterial phase computed tomography predicts biological aggressiveness | Q37669053 | ||
Advanced imaging of chronic pancreatitis | Q37738068 | ||
EUS diagnosis of chronic pancreatitis | Q37769607 | ||
High prevalence of pancreatic cysts detected by screening magnetic resonance imaging examinations | Q37771750 | ||
Serum biomarkers for improved diagnostic of pancreatic cancer: a current overview | Q37824829 | ||
The current role of contrast-enhanced ultrasound (CEUS) imaging in the evaluation of renal pathology. | Q37878398 | ||
Endoscopic ultrasound identifies synchronous pancreas cystic lesions not seen on initial cross-sectional imaging | Q37894547 | ||
Cyst features and risk of malignancy in intraductal papillary mucinous neoplasms of the pancreas: a meta-analysis | Q38082269 | ||
Technologies for imaging the normal and diseased pancreas | Q38102109 | ||
Screening and surgical outcomes of familial pancreatic cancer | Q38103113 | ||
Stromal expression of SPARC in pancreatic adenocarcinoma | Q38108253 | ||
Circulating non-coding RNAs as biomarkers of beta cell death in diabetes. | Q38147178 | ||
Pancreatic cancer cell-derived vascular endothelial growth factor is biologically active in vitro and enhances tumorigenicity in vivo | Q38302219 | ||
Pancreatic Solid and Cystic Neoplasms: Diagnostic Evaluation and Intervention | Q38576942 | ||
Acute pancreatitis: international classification and nomenclature | Q38646576 | ||
P433 | issue | 2 | |
P407 | language of work or name | English | Q1860 |
P304 | page(s) | 97-109 | |
P577 | publication date | 2016-11-09 | |
P1433 | published in | Nature Reviews Gastroenterology & Hepatology | Q2108255 |
P1476 | title | Imaging in pancreatic disease | |
P478 | volume | 14 |
Q88956143 | An Innovation for Treating Orthotopic Pancreatic Cancer by Preoperative Screening and Imaging-Guided Surgery |
Q52519464 | Chronic pancreatitis. |
Q89837430 | Clinical Translation of a 68Ga-labeled Integrin αvβ6-targeting Cyclic Radiotracer for PET Imaging of Pancreatic Cancer |
Q90115346 | Exosomes and pancreatic diseases: status, challenges, and hopes |
Q47712898 | Molecular imaging of pulmonary diseases |
Q92394162 | Molecular imaging of β-cells: diabetes and beyond |
Q52579542 | Motion model ultrasound localization microscopy for preclinical and clinical multiparametric tumor characterization. |
Q42365615 | Pancreatic imaging: Current status of clinical practices and small animal studies |
Q51837676 | Paraduodenal pancreatitis: benign and malignant mimics at MRI. |
Q47551580 | Safety and Efficacy of AAV Retrograde Pancreatic Ductal Gene Delivery in Normal and Pancreatic Cancer Mice |
Q33703088 | Synthesis of 5-[18F]Fluoro-α-methyl Tryptophan: New Trp Based PET Agents |
Q92797540 | Targeted Molecular Imaging of Pancreatic Cancer with a Miniature Endoscope |
Search more.